Richard Bax

3.5k total citations · 1 hit paper
31 papers, 1.8k citations indexed

About

Richard Bax is a scholar working on Pharmacology, Molecular Medicine and Epidemiology. According to data from OpenAlex, Richard Bax has authored 31 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pharmacology, 12 papers in Molecular Medicine and 9 papers in Epidemiology. Recurrent topics in Richard Bax's work include Antibiotics Pharmacokinetics and Efficacy (13 papers), Antibiotic Resistance in Bacteria (12 papers) and Antibiotic Use and Resistance (8 papers). Richard Bax is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (13 papers), Antibiotic Resistance in Bacteria (12 papers) and Antibiotic Use and Resistance (8 papers). Richard Bax collaborates with scholars based in United Kingdom, United States and Australia. Richard Bax's co-authors include Anthony Coates, Yanmin Hu, Clive Page, Theresa Coates, N. A. Mullan, J. Verhoef, C Carbon, Michael G. Hutchison, A. Featherstone and Samantha Green and has published in prestigious journals such as Nature Medicine, Nature Reviews Drug Discovery and Clinical Infectious Diseases.

In The Last Decade

Richard Bax

30 papers receiving 1.6k citations

Hit Papers

The future challenges facing the development of new antim... 2002 2026 2010 2018 2002 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The future challenges facing the development of new antimicrobial drugs
    2002 570 citations Anthony Coates, Yanmin Hu et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Bax United Kingdom 19 424 409 389 346 315 31 1.8k
R. Guidos United States 3 407 1.0× 469 1.1× 746 1.9× 368 1.1× 290 0.9× 3 1.9k
Roger L. White United States 22 620 1.5× 378 0.9× 565 1.5× 416 1.2× 546 1.7× 52 2.1k
B. van Klingeren Netherlands 25 407 1.0× 229 0.6× 425 1.1× 590 1.7× 557 1.8× 73 1.9k
Agnès Girard United States 19 478 1.1× 308 0.8× 359 0.9× 558 1.6× 347 1.1× 39 1.5k
Patrizia Pecile Italy 17 236 0.6× 327 0.8× 521 1.3× 296 0.9× 391 1.2× 52 1.5k
Stefan Tyski Poland 25 451 1.1× 567 1.4× 311 0.8× 221 0.6× 244 0.8× 128 2.0k
Francesca Prestinaci Italy 4 190 0.4× 584 1.4× 577 1.5× 258 0.7× 258 0.8× 7 2.5k
J C Pechère Switzerland 25 570 1.3× 382 0.9× 738 1.9× 429 1.2× 327 1.0× 65 1.8k
D. S. Reeves United Kingdom 25 680 1.6× 287 0.7× 480 1.2× 438 1.3× 328 1.0× 94 1.8k
Kevin S. Akers United States 25 236 0.6× 562 1.4× 381 1.0× 350 1.0× 338 1.1× 72 1.8k

Countries citing papers authored by Richard Bax

Since Specialization
Citations

This map shows the geographic impact of Richard Bax's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Bax with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Bax more than expected).

Fields of papers citing papers by Richard Bax

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Bax. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Bax. The network helps show where Richard Bax may publish in the future.

Co-authorship network of co-authors of Richard Bax

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Bax. A scholar is included among the top collaborators of Richard Bax based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Bax. Richard Bax is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bax, Richard & Samantha Green. (2015). Antibiotics: the changing regulatory and pharmaceutical industry paradigm. Journal of Antimicrobial Chemotherapy. 70(5). 1281–1284. 36 indexed citations
2.
Bax, Richard, et al.. (2012). Introduction to Antibiotic Resistance. Handbook of experimental pharmacology. 1–12. 7 indexed citations
3.
Coates, Theresa, Richard Bax, & Anthony Coates. (2009). Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects. Journal of Antimicrobial Chemotherapy. 64(1). 9–15. 136 indexed citations
4.
Williams, Keith J. & Richard Bax. (2009). Challenges in developing new antibacterial drugs.. PubMed. 10(2). 157–63. 28 indexed citations
5.
Bax, Richard. (2007). Development of a twice daily dosing regimen of amoxicillin/clavulanate. International Journal of Antimicrobial Agents. 30. 118–121. 18 indexed citations
6.
Mauck, Christine, et al.. (2004). Male tolerance study of 1% C31G. Contraception. 70(3). 221–225. 18 indexed citations
7.
Mauck, Christine, Mitchell D. Creinin, Kurt T. Barnhart, et al.. (2004). A phase I comparative postcoital testing study of three concentrations of C31G. Contraception. 70(3). 227–231. 26 indexed citations
8.
Mauck, Christine, Debra H. Weiner, Mitchell D. Creinin, et al.. (2004). A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II. Contraception. 70(3). 233–240. 44 indexed citations
9.
Bax, Richard, Karen Douville, Dominique McCormick, et al.. (2002). Microbicides—evaluating multiple formulations of C31G. Contraception. 66(5). 365–368. 36 indexed citations
10.
Coates, Anthony, Yanmin Hu, Richard Bax, & Clive Page. (2002). The future challenges facing the development of new antimicrobial drugs. Nature Reviews Drug Discovery. 1(11). 895–910. 570 indexed citations breakdown →
11.
Bax, Richard. (2001). How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development. Clinical Microbiology and Infection. 7. 46–48. 4 indexed citations
12.
Bax, Richard, R. Bywater, Herman Goossens, et al.. (2001). Surveillance of antimicrobial resistance — what, how and whither?. Clinical Microbiology and Infection. 7(6). 316–325. 105 indexed citations
13.
Bax, Richard, N. A. Mullan, & J. Verhoef. (2000). The millennium bugs — the need for and development of new antibacterials. International Journal of Antimicrobial Agents. 16(1). 51–59. 117 indexed citations
14.
Reeves, D. S., R. Finch, Richard Bax, et al.. (1999). Self-medication of antibacterials without prescription (also called ‘ over-the-counter’ use). Journal of Antimicrobial Chemotherapy. 44(2). 163–177. 33 indexed citations
15.
Bax, Richard, Roy M. Anderson, Jeremy Crew, et al.. (1998). Antibiotic resistance - what can we do?. Nature Medicine. 4(5). 545–546. 67 indexed citations
16.
Carbon, C & Richard Bax. (1998). Regulating the use of antibiotics in the community. BMJ. 317(7159). 663–665. 55 indexed citations
17.
Bax, Richard. (1997). Antibiotic Resistance: A View from the Pharmaceutical Industry. Clinical Infectious Diseases. 24(Supplement_1). S151–S153. 40 indexed citations
18.
Davey, Peter, et al.. (1996). Growth in the use of antibiotics in the community in England and Scotland in 1980-93: Table 1. BMJ. 312(7031). 613–613. 64 indexed citations
19.
Bax, Richard, et al.. (1989). The pharmacokinetics of meropenem in volunteers. Journal of Antimicrobial Chemotherapy. 24(suppl A). 311–320. 135 indexed citations
20.
Bax, Richard & Joanne Young. (1981). Cefotaxime: United Kingdom clinical trial results in the treatment of severe infections.. PubMed. 7(6). 401–9. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Guidos Breakdown of academic impact, for papers by Roger L. White Breakdown of academic impact, for papers by B. van Klingeren Breakdown of academic impact, for papers by Agnès Girard Breakdown of academic impact, for papers by Patrizia Pecile Breakdown of academic impact, for papers by Stefan Tyski Breakdown of academic impact, for papers by Francesca Prestinaci Breakdown of academic impact, for papers by J C Pechère Breakdown of academic impact, for papers by D. S. Reeves Breakdown of academic impact, for papers by Kevin S. Akers
Rankless by CCL
2026